GSK(US:GSK) Prnewswireยท2025-03-04 10:45Core Viewpoint - A class action securities lawsuit has been filed against GSK plc, alleging securities fraud that affected investors between February 5, 2020, and August 14, 2022 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that GSK misled investors regarding the removal of Zantac from the market, stating it was based on available information and regulatory correspondence, while in reality, GSK had known about the source of NDMA for nearly 40 years prior to the withdrawal [2]. - GSK assured investors that there was no evidence linking ranitidine therapy to cancer, which the lawsuit argues was materially false or misleading [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until April 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].